THE MEDICAL RESEARCH, INFRASTRUCTURE, AND HEALTH SERVICES FUND OF THE TEL-AVIV Patent applications |
Patent application number | Title | Published |
20130204122 | DEVICE FOR USE IN ELECTRO-BIOLOGICAL SIGNAL MEASUREMENT IN THE PRESENCE OF A MAGNETIC FIELD - A measurement device is presented for use in an EEG measurement performed in the presence of a magnetic field. The device comprises a wiring array for connecting an electrodes arrangement to an electroencephalogram (EEG) monitoring device. The wiring array comprises a plurality of sampling lines arranged to form a first group of sampling lines arranged in a spaced-apart substantially parallel relationship extending along a first axis, at least some of said sampling lines being wire bundles of said first group comprising a plurality of first wires for connecting to a corresponding first plurality of electrodes of said EEG electrodes arrangement; and a second group of sampling lines arranged in a spaced-apart substantially parallel relationship extending along a second axis, intersecting with said first axis, such that said second group of bundles crosses said first group of bundles to form a net structure, at least some of said sampling lines being wire bundles of said second group comprising a plurality of second wires for connecting to a corresponding second plurality of electrodes of said EEG electrodes' arrangement. The wiring array is configured and operable for transmitting a signal measured by the respective electrodes to the EEG monitoring device, enabling generation of EEG data indicative of the neural signal profile along tow directions and characterized by reduced motion artifact and/or reduced gradient artifact associated with the presence of the magnetic field during the EEG measurement. | 08-08-2013 |
20130133089 | HIGH AFFINITY LEPTINS AND LEPTIN ANTAGONISTS - Leptin muteins, in particular leptin antagonists, with increased binding affinity to leptin receptor are provided. These compounds as well as pharmaceutical composition comprising them are useful for the treatment of any disorder in which a non-desirable or deleterious activity of endogenous leptin or an altered innate immune response is implicated. | 05-23-2013 |